Nektar Therapeutics reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 24.14 million compared to USD 23.63 million a year ago. Net loss was USD 45.84 million compared to USD 59.05 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.31 a year ago.
For the nine months, revenue was USD 66.24 million compared to USD 70.03 million a year ago. Net loss was USD 233.98 million compared to USD 308.51 million a year ago. Basic loss per share from continuing operations was USD 1.23 compared to USD 1.65 a year ago.